Active, not recruitingPHASE1, PHASE2NCT05882734
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Principal Investigator
- Medical ResponsibleMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Intervention
- M1774(drug)
- Enrollment
- 61 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- UCLA Hematology and Oncology - Santa Monica, Santa Monica, California, United States
- UPMC Cancer Center, Pittsburgh, Pennsylvania, United States
- Tennessee Cancer Specialists - Biomedical Research, Knoxville, Tennessee, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Millennium Research & Clinical Development, Houston, Texas, United States
- Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
- Institut Jules Bordet - Department of Institut Jules Bordet', Anderlecht, Belgium
- UZA - Oncology, Edegem, Belgium
- Jessa Ziekenhuis Hospital, Hasselt, Belgium
- Universitair Ziekenhuis Brussel - UZB, Jette, Belgium
- UZ Leuven, Leuven, Belgium
- CHU de Liège - PARENT, Liège, Belgium
- CHU Angers - Hôpital Larrey - Service de Pneumologie, Angers, France
- Centre Hospitalier Intercommunal de Créteil - Service de Pneumologie, Créteil, France
- CHU Limoges - Hôpital Dupuytren - Unite d'Oncologie Thoracique et Cutanée, Limoges, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Merck KGaA, Darmstadt, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05882734 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital